GAMT: A Potential Drug Target for Cancer and Other Diseases (G2593)

Target Name: GAMT

NCBI ID: G2593

GAMT

GAMT: A Potential Drug Target for Cancer and Other Diseases

GAMT (GAMT-伪-glutamyl transferase), also known as PIG2, is a protein that is expressed in various tissues throughout the body. It is involved in the transfer of glutamyl groups from the amino acid glutamic acid to other amino acids, which plays a crucial role in protein synthesis and modification. GAMT is also known as a potential drug target and has been identified as a biomarker for various diseases, including cancer.

GAMT is a member of the glycine kinase family 2 (GK2) and is localized to the endoplasmic reticulum (ER) and the cytoplasm. It consists of a catalytic active site, a regulatory region, and a C-terminus. The catalytic active site is responsible for the transfer of glutamyl groups, while the regulatory region is responsible for regulating the activity of the enzyme. The C-terminus of GAMT is involved in its stability and in its interactions with other proteins.

GAMT is involved in the regulation of protein synthesis, including the translation of mRNAs into proteins. It has been shown to play a role in the regulation of various proteins, including the transcription factor nuclear factor E2F1, which is involved in the regulation of cell growth, differentiation, and apoptosis. GAMT has also been shown to play a role in the regulation of the protein kinase B-cr, which is involved in the regulation of cell survival and apoptosis.

In addition to its role in protein synthesis, GAMT is also involved in the regulation of protein degradation. It has been shown to play a role in the degradation of the protein known as p16INK4a, which is involved in the regulation of cell growth and apoptosis. This suggests that GAMT may have a negative role in the regulation of cell growth and may be a potential therapeutic target for diseases associated with overgrowth or cancer.

GAMT has also been shown to play a role in the regulation of cellular stress responses. It has been shown to be involved in the regulation of the stress protein known as Hsp70, which is involved in the regulation of cellular stress responses and is a potential therapeutic target for diseases associated with cellular stress.

GAMT is also involved in the regulation of cellular signaling pathways, including the regulation of the tyrosine kinase signaling pathway. It has been shown to play a role in the regulation of the tyrosine kinase signaling pathway in the regulation of cell survival and apoptosis.

In conclusion, GAMT is a protein that is involved in the regulation of various cellular processes, including protein synthesis, degradation, stress responses, and signaling pathways. Its role in these processes makes it a potential drug target and a biomarker for various diseases, including cancer. Further research is needed to fully understand the function of GAMT and to develop effective treatments for diseases associated with its dysfunction.

Protein Name: Guanidinoacetate N-methyltransferase

Functions: Converts guanidinoacetate to creatine, using S-adenosylmethionine as the methyl donor (PubMed:26003046, PubMed:24415674, PubMed:26319512). Important in nervous system development (PubMed:24415674)

The "GAMT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GAMT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets